Spravato Side Effects: What to Expect

Spravato (esketamine) is a nasal spray with its own FDA prescribing label, its own boxed warning, and its own mandatory monitoring program — separate from the side-effect profile of generic IV or injected ketamine, even though the two drugs are chemically related. If you're weighing Spravato specifically, the questions that matter most are usually about what the label actually says, why every dose happens under supervision, and what the required two-hour observation window and driving restriction look like in practice. This guide sticks to that — well-established, published label information, not medical advice. For ketamine's general side-effect profile across infusions, injections, and oral programs, see is ketamine therapy safe; for a side-by-side of Spravato and IV ketamine, see IV ketamine vs. Spravato.

What Makes Spravato's Side-Effect Profile Different

Esketamine is a single-molecule version of ketamine, delivered as a nasal spray rather than an infusion or injection. It's the only ketamine-related medicine with FDA approval for a psychiatric indication — treatment-resistant depression, and depressive symptoms in adults with major depressive disorder who have suicidal thoughts or actions — which means it went through a clinical trial and labeling process that generic, off-label ketamine never has. That approval came with conditions: Spravato can only be administered at a certified clinic, self-dosed under direct observation, with specific monitoring requirements written into the label itself. Those conditions are the reason this page exists separately from a general ketamine side-effects guide — the monitoring structure is part of the side-effect story, not a footnote to it.

Common Spravato Side Effects, From the FDA Label

These are the effects reported most often — at a rate of 5% or higher — in the clinical trials that supported Spravato's approval:

• Dissociation: a sense of detachment from your body, surroundings, or the passage of time. This is the most consistently reported effect and is closely tracked during the observation period.
• Dizziness and vertigo: a spinning or unsteady sensation, usually most pronounced in the first 40 minutes after dosing.
• Sedation: drowsiness or a heavy, sleepy feeling that's part of why you can't drive yourself home afterward.
• Nausea and vomiting: among the more commonly reported physical effects, sometimes managed with a pre-treatment anti-nausea medication.
• Increased blood pressure: a temporary rise during and shortly after dosing, checked at set intervals throughout the visit.
• Hypoesthesia: numbness or tingling, most often around the mouth or extremities.
• Anxiety and lethargy: some patients report feeling more anxious during dosing, while others describe low energy or fatigue afterward.
• Feeling "drunk" or euphoric mood changes: a subjective intoxicated feeling or a shift in mood, both listed on the label as expected treatment-session effects.

Nearly all of these are confined to the dosing session and the observation period that follows, which is the entire design premise behind requiring in-clinic monitoring rather than allowing Spravato to be taken at home.

Dose also matters. Spravato is prescribed at 56mg or 84mg, and the clinical trial data shows side effects tend to track with the higher dose — more patients on 84mg reported dissociation, dizziness, and blood pressure increases than patients on 56mg. Frequency of dosing changes over the course of treatment too: the induction phase runs twice weekly for the first month, then tapers to weekly and eventually every one to two weeks during maintenance. Many patients describe the side-effect intensity easing somewhat as their prescriber settles on a stable, individualized dose and the body adjusts to a predictable schedule, though that pattern varies by person and isn't something the label guarantees.

Spravato's Boxed Warning: What It Actually Covers

Spravato carries an FDA boxed warning — the agency's strongest labeling requirement — built around two connected risk categories. A boxed warning means the FDA wants a risk highlighted prominently and managed with specific safeguards; it doesn't mean a drug shouldn't be prescribed.

The first category is sedation, dissociation, and misuse or abuse potential. Because esketamine can impair attention, judgment, thinking, reaction speed, and motor skills for a period after dosing, and because ketamine-class drugs carry a recognized potential for misuse (esketamine is a Schedule III controlled substance), the label requires that Spravato only be dispensed and administered through a restricted program — the REMS discussed below — rather than sent home with patients.

The second category is the same class-wide warning carried by antidepressant medications generally: an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, with the label specifically calling out close monitoring for patients up through age 24. This is a labeling requirement that applies broadly across antidepressant classes, not a finding unique to Spravato, and it's a reason prescribers watch closely for any worsening of mood or new suicidal thinking, especially early in treatment or after a dose change. If you or someone you know is having thoughts of suicide, the 988 Suicide & Crisis Lifeline is available by call or text, any time.

Why Every Dose Happens at a REMS-Certified Clinic

REMS stands for Risk Evaluation and Mitigation Strategy — an FDA program attached to drugs whose risks require extra structure beyond a standard prescription. Spravato's REMS requires that the drug never leave a certified healthcare setting: you self- administer the nasal spray under direct observation, rather than filling a prescription at a pharmacy and dosing on your own. Clinics have to be specifically certified to dispense and administer it, staff have to be trained on the monitoring requirements, and patients have to be enrolled in the program before a first dose. That built-in structure is also part of why Spravato tends to be more consistently covered by insurance than generic ketamine infusions — it's billed as an FDA-approved, in-office administered medication with a formal monitoring protocol, which insurers already have a framework for handling.

The 2-Hour Observation Window

After you self-administer the nasal spray — typically two sprays per device, sometimes a second device five minutes later depending on your prescribed dose — a member of the clinical team stays with you through the entire observation period, which runs at least two hours from the time of that first dose. During that window, staff check blood pressure and heart rate at intervals, watch for how dissociation and sedation are tracking, and confirm you're oriented and stable. You're not free to leave once you feel better on your own timeline — the label sets specific discharge criteria, and a clinician has to sign off that you've met them before the visit ends. Most patients describe the observation period as the slow part of the appointment, with the acute dissociative effects fading well before the full two hours are up.

Blood Pressure Monitoring During and After Treatment

A temporary rise in blood pressure is one of the most consistently reported effects on the label, so blood pressure gets checked before dosing to establish a baseline, again around the time effects typically peak, and once more before you're discharged. That's also why intake screening for Spravato asks pointed questions about cardiovascular history: uncontrolled or severe hypertension is a condition clinics screen for before starting treatment, and the label specifically lists aneurysmal vascular disease (including history of intracranial hemorrhage) and arteriovenous malformation as conditions requiring caution, given the cardiovascular effect of dosing. If blood pressure rises above a set threshold during a session, the monitoring clinician can delay the next scheduled dose or adjust the treatment plan. For the fuller list of conditions a clinic screens for before starting treatment, see who is a candidate for ketamine therapy.

The Driving Restriction After Spravato

The label is specific on this point: patients should not drive, operate heavy machinery, or engage in other activities that require full mental alertness on the day of treatment, even once the two-hour observation period is complete and you feel back to normal. That restriction lifts the next day, after a full night's sleep — not simply after a few hours pass. In practice, this means arranging a ride home is a requirement for every session, not just the first one, and it's something REMS-certified clinics confirm before dosing rather than leaving to chance afterward.

Long-Term Side Effects of Spravato

Most of what's documented about extended Spravato use comes from the maintenance-phase clinical trials that supported its approval, which followed patients on an ongoing dosing schedule for roughly a year after the initial induction series. Those trials didn't identify new categories of risk beyond the same session-level effects — dissociation, sedation, a rise in blood pressure — recurring with each subsequent dose rather than accumulating into something different. Because Spravato is dispensed only through REMS-certified clinics, adverse events are also reported back through that program over time, which gives regulators an ongoing view of the drug's safety record that generic, off-label ketamine doesn't have in the same structured way. That said, data on Spravato use extending years beyond the trial period is more limited than for medications that have been on the market for decades, which is part of why prescribers typically reassess an open-ended maintenance schedule periodically with each patient rather than treating it as indefinite by default.

Who Should Use Extra Caution With Spravato

Beyond the cardiovascular and blood pressure conditions already covered above, the Spravato label calls out aneurysmal vascular disease and arteriovenous malformation as conditions warranting particular caution, given the drug's cardiovascular effect during dosing. Standard ketamine-treatment screening — uncontrolled hypertension, recent cardiac events, a history of psychosis, pregnancy or breastfeeding, and active substance use disorder — applies to Spravato as well. None of this is a substitute for a full intake review: a REMS-certified prescriber will walk through your specific health history, including every medication and supplement you take, before your first dose.

Other medications you take can also change how a Spravato session feels. Combining esketamine with other sedating drugs — benzodiazepines, opioids, or alcohol in particular — can deepen sedation and increase the risk of excessive drowsiness after a session, which is part of why intake forms ask for a full medication list rather than just a summary. Psychostimulants and MAOIs are among the other drug classes a prescriber will want to review carefully before your first dose, since interactions can affect blood pressure or how the sedative effects play out.

Finding a REMS-Certified Spravato Provider

Because Spravato can only be administered at a certified location, confirming REMS enrollment is one of the first things worth checking before you book — a legitimate clinic will be able to confirm its certification without hesitation. You can browse clinics offering Spravato or search ketamine clinics near you to compare providers by location and treatment type before scheduling a consultation.

Frequently Asked Questions

Sources: FDA prescribing information for Spravato (esketamine) and its associated REMS program requirements. Informational only — not medical advice. Talk with a licensed clinician about your health history before starting treatment.